

ARM WORKSHOP: EVOLUTION OF THE CGT SECTOR


LOCATION: Washington, DC, 20 F Street, NW

FORMAT: Hybrid: In-Person & Virtual Link

DATE: November 5-6, 2025

DAY 1 – NOVEMBER 5, 2025

- 8:00 – 9:00am** **Registration & Breakfast**
- 9:00 – 9:15am** **Opening Remarks**
Tim Hunt, CEO, Alliance for Regenerative Medicine
- 9:15 – 10:00am** **Session 1: Scale-In: Baby KJ – what’s next?**
- 9:15 – 9:35am** **Keynote**
- Vanessa Almendro-Navarro, Vice President, Head of Science & Technology Innovation, Danaher Corporation
- 9:35 – 10:15am** **Panel Discussion**
Moderator: Vanessa Almendro-Navarro, Vice President, Head of Science & Technology Innovation, Danaher Corporation
- Panelists:
- Mark Duckworth, Sr. Director Cellular and Gene Therapy Operations, CHOP
 - Ran Zheng, CEO, Landmark Bio
 - Mimi Lee, Chief of Precision Medicine, Gene Dx
- 10:15 – 10:30am** **Morning Break**
- 10:30 – 11:15am** **Session 2: Scale-Out: Bioprocessing Autologous Therapies For Industrial Scale**
Chair: Sadik Kassim, CSO/CTO (Omics Solutions/Genomic Medicines), Danaher Corporation
- Presentations:**
- Barbara Ressler, VP of Process Sciences, Roslin CT
 - Neil Sheppard, Head of the Therapeutic Innovation in NK cell (THINK) Lab & Adj. Assoc. Prof. of Path & Lab Medicine, University of Pennsylvania & Founder, BlueWhale Bio
- Joint Q&A with presenters
- 11:15am – 12:00pm** **Panel discussion**
Moderator: Sadik Kassim, CSO/CTO (Omics Solutions/Genomic Medicines), Danaher Corporation
- Panelists:
- Audrey Greenberg, Mayo Venture Partner & Chair, Department of Business Development, Mayo Clinic



- Eytan Abraham, Chief Commercial and Technology Officer, Minaris Advanced Therapies
- Chris Choi, Senior Vice President Industry Partnerships; Associate Professor of Oncology, Roswell Park Comprehensive Cancer Center
- Madan Jagasia, CEO, Obsidian Therapeutics

12:00 – 1:00pm

Lunch Break & Networking

1:00 – 2:00pm

Session 3: Advances in Viral and Non-Viral Delivery

Chair: Andy Holt, Chief Commercial Officer, Viralgen

Presentations: Delivery

- Andras Nagy, Professor, Department of Obstetrics & Gynaecology and Institute of Medical Science, University of Toronto, Tier 1 Canada Research Chair in Stem Cells and Regeneration
- April Sena, VP Technical Operations, Life Edit Therapeutics
- Adrian Veres, Co-founder and CSO, Dyno Therapeutics

Joint Q&A with presenters

2:00 – 2:45pm

Panel Discussion: Delivery

Moderator: Andy Holt, Chief Commercial Officer, Viralgen

Panelists:

- Olivier Danos, Chief Scientific Officer, REGENXBIO Inc
- Jonathan Schwartz, Chief Scientific and Gene Therapy Officer at Rocket Pharmaceuticals

2:45 – 3:00pm

Afternoon Break

3:00 – 4:00pm

Session 4: Scale-Up: Advancing allogeneic cell and gene therapy products

Chair: Sharon Anderson, VP, Scientific Affairs, Alliance for Regenerative Medicine

Presentations:

- Benjamin Fryer, CEO, Pluristyx
- Alison Burkart, Director, Analytical Development, Astellas Pharma US
- David Smith, VP of Development, Made Scientific

Joint Q&A with presenters

4:00 – 4:45pm

Panel Discussion:

Moderator: Ruby Tsai, President, Applied Stem Cell Inc

Panelists:

- David Smith, VP of Development, Made Scientific
- Sara Mills, VP, Regulatory Affairs, Artiva
- Richard Kincaid, CEO, Healios NA
- Sharon Anderson, VP, Scientific Affairs, Alliance for Regenerative Medicine

4:45 – 5:00pm

Day 1 Concluding Remarks

Natalie Fekete, Sr. Manager, Scientific Affairs, Alliance for Regenerative Medicine

5:00 – 6:30pm

Networking Reception

Lobby of 20F St

DAY 2 – NOVEMBER 6, 2025

- 8:00 – 9:00am Registration & Breakfast
- 9:00 – 9:15am **Day 2 Opening Remarks**
John Aguilar, Director for Alliance Development, Alliance for Regenerative Medicine
- 9:15 – 10:15am **Session 5: Evolution of the patient participation in CGT therapies**
Chair: John Aguilar, Director for Alliance Development, ARM
- Panel:**
- Panteli Theocharous, Director of the Board of the Malcom Orlando Ivy Foundation (TMOIF)
 - Charlene Son Rigby, CEO, Global Genes
 - Bradley Watts, CAR-T Recipient and Patient Advocate
 - Joe Katakowski, Director of Research, RTW Foundation
- 10:15 – 10:30am **Session 6: Expanding Patient Access Towards Communities**
Chair: Joe DePinto, Head of Cell, Gene, and Advanced Therapies, McKesson
- Presentation: Introduction to the Topic**
- Joe DePinto, Head of Cell, Gene, and Advanced Therapies, McKesson
- 10:30 – 11:15am **Panel Discussion:**
- Erica Cischke, VP, Gov Affairs, Alliance for Regenerative Medicine
 - Robb Richards, Corporate Director, Cell Therapy and Transplant, Penn Medicine, University of Pennsylvania Health System
 - Christine Pfaff, Director of Clinical Initiatives, Community Oncology Alliance (COA)
 - George Eastwood, Executive Director, Emily Whitehead Foundation
- 11:15 – 11:30am Morning Break
- 11:30am – 12:00pm **Session 7: Real-Time Release: Harnessing Advanced Analytics**
Chair: Matthew Hewitt, Vice President, CTO Manufacturing Business Division at Charles River Laboratories
- Presentations:**
- Matthew Hewitt, Vice President, CTO Manufacturing Business Division at Charles River Laboratories
 - Michael Brewer, Director, Global Principal Consultant, Regulatory for the BioProduction Division (BPD), Thermo Fisher Scientific
 - Lori Daane, Chief Scientific Officer, Bionique Testing Laboratories LLC
- 12:00 – 12:30pm **Panel Discussion**
All presenters from this session
- 12:30 – 1:30pm Lunch & Networking
- 1:30 – 2:30pm **Session 8: Regulatory Session**
- Panel Discussion: Platforms & Pilots: Making Risk-Based Regulation Predictable for CGT**
Moderator:

- Kimberly Benton, Master Principal, Head of Regulatory, Dark Horse Consulting Group Inc.

Panelists:

- Michael Lehmicke, Sr. VP for Scientific Affairs, Alliance for Regenerative Medicine
- Christopher Shilling, Chief Regulatory Officer, Forge Biologics
- Sara Mills, VP, Regulatory Affairs, Artiva

2:30 – 2:45pm

Day 2 Concluding Remarks

Sharon Anderson, VP, Scientific Affairs, Alliance for Regenerative Medicine